(CercleFinance.com) – Credit Suisse initiated coverage of Eli Lilly shares on Friday with an ‘outperformance’ opinion and a price target of 395 dollars.
In a research note, the broker points out that the American pharmaceutical group has been able to generate “remarkable” performance so far, despite a complicated market context.
With a stock market valuation that is now moving to historic highs (PER of 36.8x at a one-year horizon), the whole question is whether this dynamic is set to continue, explains the broker.
On this point, Credit Suisse says it is ‘optimistic’, forecasting growth at the top of the sector’s performance in the medium and long term, an important element in an environment increasingly marked by risk aversion, he concludes. .
Copyright © 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
